Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers

Soudeh Ghafouri-Fard1, Ali Noie Alamdari2, Yashar Noee Alamdari3, Atefe Abak4, Bashdar Mahmud Hussen5,6, Mohammad Taheri7,8* and Elena Jamali9*

Abstract

PI3K/AKT pathway is an important pathway in the carcinogenesis since it has central impacts in the regulation of metabolic pathways, cell proliferation and survival, gene expression and protein synthesis. This pathway has been reported to be dysregulated in several types of cancers. In the current review, we summarize the role of this signaling pathway in squamous cell carcinomas (SCCs) originated from different parts of body cervix, oral cavity, head and neck and skin. The data presented in the current review shows the impact of dysregulation of PI3K/AKT pathway in survival of patients with SCC. Moreover, targeted therapies against this pathway have been found to be effective in reduction of tumor burden both in animal models and clinical settings. Finally, a number of molecules that regulate PI3K/AKT pathway can be used as diagnostic markers for different types of SCCs.

Keywords: PI3K/AKT pathway, Squamous cell carcinoma

Introduction

PI3K/AKT pathway has important roles in the carcinogenesis since it has central impact in the regulation of metabolic pathways, cell proliferation and survival, gene expression and protein synthesis [1]. As a multimember family of heterodimeric lipid kinases, PI3Ks are classified into three distinct classes. Class IA PI3Ks are induced by receptor tyrosine kinases such as p110 catalytic subunit as well as p85-like regulatory subunits [1]. Class IB PI3Ks are induced by G protein-coupled receptors and regulatory subunits. Class II PI3Ks includes three proteins, namely PIK3C2A, PIK3C2B and PIK3C2G. Finally PIK3C3 is regarded as the single member of class III PI3Ks. PI3Ks can be induced by several upstream cell-surface receptors. In response to these stimuli, class I proteins catalyze the conversion of PI(4,5)P2 to the second messenger PI(3,4,5)P3 in response to PI(3,4)P2, AKT is recruited on the cell membrane through its PH domain and exerts its catalytic roles through activation of a PDK1-induced threonine phosphorylation and mTORC2-mediated serine phosphorylation. These phosphorylation events occur at specific sites of AKT1-AKT3. In response to increase in PI(3,4,5)P3 levels and to a lesser extent accumulation of PI(3, 4)P2, AKT is recruited on the cell membrane through its PH domain and exerts its catalytic roles through activation of a PDK1-induced threonine phosphorylation and mTORC2-mediated serine phosphorylation. These phosphorylation events occur at specific sites of AKT1, AKT2 and AKT3 [4, 5]. The effects
of AKT on regulation of important downstream effectors including FOXO, mTOR and GSK3b endows this molecule the ability to influence cell proliferation and survival, genome stability, and metabolic pathways [1]. PI3K/AKT pathway has been reported to be dysregulated in several types of cancers. In the current review, we summarize the role of this signaling pathway in squamous cell carcinomas (SCCs) originated from different parts of body cervix, oral cavity, head and neck and skin.

**Cervical cancer**

Hou et al. have assessed the clinical outcomes of individuals with metastatic or recurrent cervical cancer during a phase I clinical trial. They have reported longer survival of patients with SCC of the cervix who had PIK3CA mutations compared with those without PIK3CA mutations. In fact, their results have shown that matched therapies against the activated PI3K/AKT/mTOR pathway have significant clinical benefit [6]. Another study in the context of cervical SCC has shown over-expression of the endogenous inhibitor of mTOR complexes DEPTOR in these cells and tissues. DEPTOR silencing has enhanced apoptosis of these cells via increasing expression of p38 MAPK and suppression of PI3K/AKT activity through feed-back suppression from mTORC1-S6K. Moreover, knock down of this gene has led to reduction of levels of nitric oxide synthases iNOS and eNOS, and enhancement of activity of ERK1/2 and p38 MAPKs. Moreover, DEPTOR could affect ERK1/2 expression in through modulation of AKT. Cumulatively, DEPTOR increases survival of cervical SCC cells and its knock down leads to cell apoptosis through distinctive impacts on PI3K/AKT and p38 MAPK [7]. Moreover, the over-expressed receptor for advanced glycation endproducts (RAGE) has been shown to be involved in the pathogenesis of cervical SCC through modulation of PI3K/AKT activity. This protein has been found to promote proliferation of cervical SCC, enhance expression of PCNA, inhibit cell apoptosis along, reduce Bax/Bcl-2 ratio, and induce activity of PI3K/AKT pathway. RAGE silencing has reduced tumor burden in a xenograft model of cervical SCC. Finally, the PI3K inhibitor LY294002 could efficiently inhibit activity of PI3K and AKT, and suppress RAGE-induced pro-proliferative and anti-apoptosis effects [8]. Table 1 shows the role of PI3K/AKT pathway in squamous cell carcinoma of cervix.

**Head and neck squamous cell carcinoma**

**Laryngeal squamous cell carcinoma (LSCC)**

Mukonal, the isolated alkaloid from the plant *Murraya koenigii* has been shown to reduce the viability of laryngeal SCC cells, induce their apoptosis and arrest them at G2/M phase possibly through suppression of activity of PI3K/AKT and MEK/ERK pathways [20]. Moreover, dehydrocostus lactone isolated from *Saussurea costus* Lipech has been found to exert cytotoxic effects in this type of cancer. This substance could inhibit viability, migration and proliferation of laryngeal SCC cells without affecting viability of normal larynx epithelial cells. Notably, dehydrocostus lactone could promote function of p53 and P21 and induce cells apoptosis through suppression of PI3K/Akt/Bad pathway and stimulation of endoplasmic reticulum stress-mediated apoptotic pathways. In vivo assays have also verified these effects [21].

Another study has shown up-regulation of FGFR1, FGFR3 and PI3K/AKT kinase expression levels in the squamous cell laryngeal cancer samples compared with non-cancerous laryngeal mucosa specimens. Notably, over-expression of PI3K/AKT kinase has been associated with a high tumor front grading. Moreover, levels of the p-PI3K regulatory kinase protein have been associated with survival rate of patients. Taken together, FGFR1, FGFR3, and downstream regulatory kinases from the PI3K/AKT pathway might be regarded as putative markers indicative of invasive properties of laryngeal cancer [22]. Table 2 shows the role of PI3K/AKT pathway in laryngeal squamous cell carcinoma.

**Esophageal squamous cell carcinoma (ESCC)**

Expression analyses esophageal cancer tissues have shown up-regulation of miR-21, PI3K, and AKT, while down-regulation of PTEN in these tissues compared with adjacent non-cancerous tissues. Notably, samples obtained from patients with lymph node metastases and poor differentiation levels had lower expression of PTEN and higher levels of PI3K and AKT proteins. Suppression of miR-21 levels in esophageal cancer cells has led to up-regulation of PTEN, down-regulation of PI3K and AKT and reduction of proliferation rate, migration, and invasion of cells. This miRNA has been found to target PTEN. Cumulatively, miR-21 has been shown to target important molecules in PTEN/PI3K/AKT signal pathway, enhancing proliferation, migration, invasiveness, and cell cycle transition, and suppressing apoptotic pathways in esophageal SCC cells [47]. Another study in esophageal SCC patients has shown correlation between p-EGFR expression and all of the other phosphorylated biomarkers. Notably, gender, N stage, and expression levels of p-AKT1 have been independently correlated with overall survival of patients. In fact, over-expression of p-AKT1 has been found to be indicative of low survival. However, levels of EGFR and p-EGFR have not been correlated with patients’ survival [48]. Moreover, dysregulation of PAFR via PI3K/AKT pathway has been reported to contribute to the progression of esophageal SCC [49].
| Samples | Cell lines | Drug/phytotherapy | Dose range | Target | Pathway | Function | Refs. |
|---------|------------|------------------|------------|--------|---------|----------|-------|
| Metastatic or recurrent cervical SCC (n=31) | – | – | – | – | – | – | [6] |
| | SiHa, ME-180, HeLa, C33A | DEPTOR siRNA | 90 nM | Bcl-2, Bcl-xl | PI3K/AKT, p38 MAPK, ERK1/2 | DEPTOR silencing via down-regulating PI3K/AKT and by up-regulating p38 MAPK could induce apoptosis | [7] |
| | SiHa, CaSki, C33A, MS751 | FPS-2M1 | 1 μM | RAGE, Bax, Bcl-2, PCNA | PI3K/AKT | Downregulation of RAGE via modulation of PI3K/AKT can activate apoptosis and inhibit cell proliferation in cervical SCC | [8] |
| Primary cervical cancer (n=70), normal cervical tissues (n=30) | HeLa, SiHa, ME-180, CaSki, C-33A, C-4I, SW756, MS751 | – | – | p27Kip1, AKT1 | PI3K/AKT | Downregulation of p27(Kip1) could be regulated via the PI3K/AKT-mediated proteasomal degradation in CC cells | [9] |
| Primary CC (n=35), normal cervical tissues (n=35) | HeLa, CaSki, SiHa, ME-180, H8 | – | – | ANRIL | PI3K/AKT | LncRNA ANRIL could promote carcinogenesis via PI3K/Akt pathway and can be considered as an indicator of poor prognosis | [10] |
| | HeLa | Nicotine | 0.1–10 μM | NF-κB | PI3K/AKT | Nicotine via induction of PI3K/AKT/NF-κB pathway promotes HeLa cell migration and invasiveness | [11] |
| Primary CC (n=93) | HeLa, CaSki | LY294002, cisplatin | 10–30 nM, 10 μM | PAK4 | PI3K/AKT | PAK4 via the PI3K/AKT pathway can contribute to the cisplatin resistance in CC cells | [12] |
| Primary CC (n=136) | HeLa | – | – | PGRN, TSC-2, p70S6K | PI3K/AKT, mTOR, ERK | Growth factor progranulin (PGRN) via the PI3K/AKT/mTOR pathway can promote tumorigenesis of CC | [13] |
| Primary CC (n=219) | HeLa, ME-180, SiHa, C33A, CaSki, MS751 | – | – | FOXC1 | PI3K/AKT | FOXC1 via the PI3K-AKT signal pathway can promote proliferation and EMT in CC | [14] |
| Samples | Cell lines | Drug/phytotherapy | Dose range | Target | Pathway | Function |
|---------|------------|-------------------|------------|--------|---------|----------|
| Primary cervical cancer (n = 174), healthy volunteers (n = 30) | – | – | – | – | PI3K/AKT, mTOR | Exosome-mediated PI3K/Akt/mTOR pathway could be considered as a diagnostic biomarker in CC |
| | SiHa, C33A, CaSki, HK-2, WI-38, HeLa | Licochalcone A (LicA) | 0–100 μM | LC3-II, Beclin-1, Atg-5/7/12, Bcl-2, Caspase-3/9, JNK1/2 | PI3K/AKT, mTOR | LicA via inactivating the PI3K/Akt/mTOR pathway could induce autophagy in CC |
| | HeLa, SiHa, CaSki | – | – | S100A6, GSK-3β, E-cadherin, N-cadherin, Vimentin, Snail, Twist | PI3K/AKT, mTOR | S100A6 via the PI3K/AKT pathway promotes proliferation and migration of CC cells |
| Primary CC (n = 72) healthy volunteers (n = 12) | CaSki | – | – | miR-433, FAK | PI3K/AKT | miR-433 via PI3K/AKT signaling by influencing expression of FAK could induce apoptosis in CC |
| Primary CC (n = 30) healthy volunteers (n = 12) | HeLa, C33A, SiHa, ME-180 | – | – | miR-338, ATF2, LC3I/II, Bax, Cyclin-D1, p27/p21, Bcl-2, Caspase-3/9 | PI3K/AKT, mTOR | miR-338 via the PI3K/AKT/mTOR pathway could modulate proliferation and autophagy in CC |
| Samples | Cell lines | Drug/phytotherapy | Dose range | Target | Pathway | Function |
|---------|------------|------------------|------------|--------|---------|----------|
| –       | AMC-HN-8, HuLa-PC | Mukonal | 0–100 µM | – | PI3K/AKT, MEK, ERK | Mukonal by affecting activity of the PI3K/AKT and MEK/ERK pathways and by promoting apoptosis and G2/M cell cycle arrest could inhibit the migration/invasion and proliferation of LC cells |
| BALB/c nu/nu | Hep-2, TU212, HBE | Dehydrocostus Lactone (DHL) | 0–10 µg/mL | Bcl-2, Bax, Bad, p53, p21, PTEN, Waf1/Cip1, Cyclin-D1, MMP-2/9, Caspase-12/9/3 | PI3K/AKT | DHL by stimulating endoplasmic reticulum (ESR) stress and inhibiting PI3K/AKT/Bad signaling pathway could inhibit cell proliferation |
| LSCC (n = 137), non-cancerous laryngeal mucosa (n = 100) | – | – | – | FGFR1, FGFR3 | PI3K/AKT | FGFR1 and FGFR3 via targeting the PI3K/AKT pathway could be involved in the invasiveness and prognosis of LSCC |
| LSCC (n = 110), laryngeal severe dysplasia (n = 30) | AMC-HN8, TU212, TU686 | – | – | FADS1, S6K1 | AKT/mTOR | Overexpression of FADS1 via activating the AKT/mTOR pathway could promote LSCC growth and migration/invasion |
| Cohort, BALB/C nude mice | Tu 177/Cis, HOK, 293 T, MRC-5, FD-LSC-1/Cis | Cisplatin | 0–25 µg/mL | miR-145-5p, circPARD3, p62, LC3B-I/II, PRKCI | AKT/mTOR | CircPARD3 through the miR-145-5p/PRKCI/AKT/mTOR axis could promote proliferation, migratory potential, invasion, and chemoresistance |
| LSCC (n = 53), ANM (n = 53), male BALB/C nude mice | FD-LSC-1, TU-177 | – | – | SKA3, PLK1, HK2, PKFB3, PDK1, PTEN, c-Myc | AKT | SKA3 via interacting with PLK1 to activate the AKT pathway by up-regulating glycolysis level could suppress the chemoresistance and proliferation of LSCC |
| – | Hep-2 | – | – | SHIP2, p21, p27, Caspase-3 | PI3K/AKT | Knockdown of SHIP2 could inactivate the PI3K/AKT pathway. Hence, it could be involved in radiosensitivity of LSCC |
| BALB/cA nu/nu | AMC-HN-8 | miR-145 | PI3K/AKT | miR-145 via the PI3K/AKT axis can inhibit the proliferation and growth of LSCC |
Table 2 (continued)

| Samples                        | Cell lines                        | Drug/phytotherapy | Dose range | Target                                      | Pathway       | Function                                                                                     | Refs. |
|--------------------------------|-----------------------------------|-------------------|------------|---------------------------------------------|---------------|-----------------------------------------------------------------------------------------------|-------|
| 16 pairs of LSCC and adjacent  | AMC-HN-8, TU212                   |                   |            | MMP-2/3, NF-kB, E-cadherin, Vimentin, Occluding, N-cadherin, | PI3K/AKT      | Knockdown of MMP2/3 via the PI3K/AKT/NF-kB axis can affect proliferation and migration of LSCC cells | [28]  |
| normal tissues                 |                                   |                   |            |                                             |               |                                                                                              |       |
| 46 pairs of LSCC and adjacent  | Hep-2, TU212, AMC-NH-8, TU686     |                   |            | MEOX2, c-Myc, Caspase-3, XIAP               | PI3K/AKT      | MEOX2 through inhibiting the PI3K/AKT pathway can suppress cancer cell viability and apoptosis | [29]  |
| normal tissues                 |                                   |                   |            |                                             |               |                                                                                              |       |
| 20 pairs of LSCC and adjacent  | Hep-2                             |                   |            | Tra2β, Bax, Bcl-2, Caspase-3               | PI3K/AKT      | Silencing of Tra2β via inhibiting the PI3K/AKT pathway leads to suppression of proliferation, invasiveness, and migration of malignant cells | [30]  |
| normal tissue                  |                                   |                   |            |                                             |               |                                                                                              |       |
| 32 pairs of LSCC and adjacent  | TU-177, TU686, TU212, AMC-NH-8,   | Curcumin          | 0–40 µM   | miR-145                                      | PI3K/AKT, mTOR| Curcumin via up-regulation of miR-145 and inhibiting PI3K/AKT, mTOR pathway could suppress LSCC progression | [31]  |
| normal tissues                 | NHOKs                             |                   |            |                                             |               |                                                                                              |       |
| 65 pairs of LSCC and adjacent  | Hep-2                             |                   |            | miR-138, EZH2                               | PI3K/AKT      | miR-138 via inhibiting the expression of EZH2 and PI3K/AKT pathway had a suppressive role in LSCC proliferation | [32]  |
| normal tissues                 |                                   |                   |            |                                             |               |                                                                                              |       |
| 40 pairs of LSCC and adjacent  | SNU899, SNU46                     |                   |            | miR-375, miR-205, PTEN, E-cadherin, Vimentin, Snail2 | AKT           | miR-375/205 via AKT-mediated EMT could be involved in the invasion and migration of LSCC | [33]  |
| normal tissues                 |                                   |                   |            |                                             |               |                                                                                              |       |
| 10 pairs of LSCC and adjacent  | Hep-2, AMC-HN-8, HaCaT            |                   |            | miR-132, FOXO1, p21, p27, Cyclin-D1         | PI3K/AKT      | miR-132 by up-regulating FOXO1 and activating the PI3K/AKT pathway could act as an oncogene in LSCC cell proliferation and growth | [34]  |
| normal tissues                 |                                   |                   |            |                                             |               |                                                                                              |       |
| –                              | D-Hep2, T-Hep2                    |                   |            | AURKA, FAK, P130, E2F4                     | PI3K/AKT      | AURKA via the FAK/PI3K/AKT axis could promote invasion and migration of LSCC tumor cells | [35]  |
| –                              | SNU-46                            |                   |            | DJ-1, PTEN                                  | PI3K/AKT, mTOR| Overexpression of DJ-1 via activating the PI3K/AKT/mTOR pathway could accelerate proliferation rate, migration, and invasion of LSCC cells | [36]  |
Table 2 (continued)

| Samples                        | Cell lines | Drug/phytotherapy | Dose range | Target                          | Pathway | Function                                                                 | Refs. |
|--------------------------------|------------|-------------------|------------|---------------------------------|---------|---------------------------------------------------------------------------|-------|
| 85 pairs of LSCC and adjacent normal tissues | Hep-2      | –                 | –          | TSLC1, Bcl-2, p21, Caspase-3, Bax, MMP-2/9 | AKT     | Overexpression of TSLC1 via AKT signaling could reduce and suppress proliferation and invasiveness and induce apoptosis of LSSC cells | [37]  |
On the other hand, vitamin E succinate could induce apoptosis of esophageal SCC cells through modulation of PI3K/AKT signaling this agent has decreased growth of EC109 cells by approximately 45 and 81% in concentrations of 10 and 100 µM, respectively [50]. Moreover, Dasatinib via suppressing the PI3K/AKT and STST3 pathways could improve sensitivity to cisplatin in esophageal SCC cells [51]. Table 3 shows the role of PI3K/AKT pathway in esophageal SCC. Figure 1 illustrates the aberrant expression of various miRNAs, which contribute to adversely modulating the PI3K/AKT signaling pathway involved in triggering several kinds of squamous cell carcinomas.

**Pharyngeal squamous cell carcinoma (PSCC)**

In patients with hypopharyngeal SCC, expression of p-Akt and p-Erk has been shown to be remarkably elevated parallel with progression of clinical stage, indicating the possible roles of PI3K/Akt and MAPK/ERK pathways in evolution and progression of this type of cancer. Notably, GDC-0980 and Refametinib have exerted cytotoxic effect on hypopharyngeal SCC cells. These agents could block cell cycle progression in G1 phase, reduce cyclin D1 and p-Rb levels and increase p27 levels. GDC-0980 could also inhibit migratory potential of these cells and reduce levels of p-PKCζ, p-Integrin β1 and uPA metastasis-related proteins. Taken together, dual suppression of PI3K/Akt and MAPK/ERK pathways by mentioned agents can be regarded as a possible strategy for treatment of hypopharyngeal SCC [60]. NVP-BEZ235 when combined with cisplatin could inhibit proliferation of hypopharyngeal SCC cells and arrest cell cycle at G2/M phase via modulation of the PI3K/AKT/mTOR pathway [61].

JARID1B, as a tumor suppressor, via the SHIP1/AKT pathway could improve differentiation of hypopharyngeal SCC cells and suppress their proliferation [62]. On the other hand, S100A11 could play an important role in the migration, carcinogenesis and protection of HPSCC from cell death induced by 5-Fu via the PI3K/AKT pathway [63]. Table 4 shows the role of PI3K/AKT pathway in pharyngeal squamous cell carcinoma.

**Oral squamous cell carcinoma (OSCC)/tongue squamous cell carcinoma (TSCC)**

Lycopene has been revealed to inhibit proliferation, migration and invasiveness of oral SCC cells as well as in vivo growth of tumors. Moreover, this substance could suppress epithelial–mesenchymal transition and activate apoptotic pathways through decreasing activity of PI3K/AKT/mTOR signaling. These effects are exerted through enhancing expressions of E-cadherin and Bax and decreasing levels of N-cadherin, p-PI3K, p-AKT, p-m-TOR, and bcl-2 [69]. Thyroquinone has also been shown to suppress invasion, proliferation and migration of oral SCC cells and induce their apoptosis via inhibiting the PI3K/AKT pathway [70]. Moreover, Licochalcone A could suppress migration, invasion, and proliferation of oral SCC cells via modulation of the PI3K/AKT pathway [71].

A number of non-coding RNAs have been reported to exert their effects in the pathogenesis of oral SCC through modulation of this pathway. This speculation has been verified by knock-down experiments. For example, suppression of lncRNA MALAT1 could inhibit invasion, migration, and proliferation of TSCC cells via suppressing the PI3K/AKT pathway and down-regulating MMP-9 [72]. Moreover, circCDR1 has been shown to improve the viability of oral SCC cells by promoting autophagy via the AKT/ERK/mTOR pathway [73]. Table 5 shows the role of PI3K/AKT pathway in oral SCC.

**Unidentified types of head and neck squamous cell carcinoma (HNSCC)**

Expression of FKBP9P1 has been shown to be increased in HNSCC samples and cells. Over-expression of this gene has been correlated with advanced T, N and clinical stages as well as poor prognosis of affected individuals. FKBP9P1 silencing has suppressed proliferation, migratory potential, and invasiveness of these cells, possibly through inhibition of PI3K/AKT signaling [38]. PFN2 is another up-regulated gene in HNSCC and cells. PFN2 silencing has suppressed proliferation, invasiveness, and migratory potential of HNSCC cells, possibly through reduction of Akt and GSK-3β phosphorylation as well as decrease in β-catenin levels. In other words, PFN2 has been shown to promote proliferation and metastatic ability of HNSCC through inducing activity of the PI3K/Akt/β-catenin pathway [39]. Similarly, DKK3 has been shown to increase the malignant properties of HNSCC via the PI3K/Akt/mTOR and MAPK pathways [40].

An in vitro study has shown that the anti-cancer agent osthol induces cell cycle arrest at G2/M phase and blocks proliferation of HNSCC cells via suppressing the PI3K/AKT pathway [41]. Finally, PI3K/AKT pathway has been shown to mediate the adaptive resistance to anti-programmed death-1 (PD1) therapy through upregulating Tim-3 [42]. Table 6 shows the role of PI3K/AKT pathway in head and neck squamous cell carcinoma.

**Cutaneous SCC**

α-mangostin has been shown to suppress skin tumor formation and growth, decrease levels of pro-inflammatory molecules and increase levels of anti-inflammatory ones both in tumor and circulation. Notably, this substance could induce autophagy of skin cancer cells and regulate
| Samples                     | Cell lines                      | Drug/phytotherapy  | Dose range  | Target              | Pathway    | Function                                                                                           | Refs. |
|-----------------------------|---------------------------------|--------------------|-------------|---------------------|------------|---------------------------------------------------------------------------------------------------|-------|
| ESCC (n = 89), NCLM         | TE11                            | –                  | –           | miR-21, PTEN        | PI3K/AKT   | miR-21 through modulation of PTEN/PI3K/AKT pathway promotes invasion/migration, proliferation, cell cycle progression, and resistance to apoptosis of ESCC cells | [47]  |
| ESCC (n = 275)              | –                               | –                  | –           | EGFR, ERK1/2, STAT3 | AKT1       | Phosphorylated AKT1 could be involved in poor prognosis in ESCC                                                                 | [48]  |
| ESCC (n = 295)              | KYSE180, KYSE140, KYSE150, KYSE30, KYSE410, KYSE450 | –                  | –           | PAFR, c-myc, survivin, MMP2/9, VEGF | PI3K/AKT, STAT3 | Dysregulation of PAFR via PI3K/AKT pathway could contribute to the progression of ESCC                                                                 | [49]  |
| –                           | EC109                           | Vitamin E succinate (VES) | 0–100 µM    | Bad, Bcl-2, Caspase-9, p70S6K, 4E-BP1, | PI3K/AKT, mTOR | VES via PI3K/AKT signaling pathway can activate apoptosis in ESCC                                                                 | [50]  |
| –                           | KYSE140, KYSE150, KYSE30, KYSE410, KYSE450, KYSE510 | Dasatinib, cisplatin | 10–500 nM, 0–15 µM | Src, c-myc, MMP-9, VEGF | PI3K/AKT, STAT3 | Dasatinib via suppressing the PI3K/AKT and STAT3 pathways could improve sensitivity to cisplatin in ESCC cells                                                                 | [51]  |
| –                           | TE13, Eca109                     | –                  | –           | miR-18a, Cyclin-D1, PTEN, S6K1, pRb-S780 | PI3K/AKT, mTOR | miR-18a by increasing cyclin-D1 via regulating the PTEN/PI3K/AKT/mTOR axis could promote cell proliferation of ESCC cells                                                                 | [52]  |
| EC109, KYSE30               | –                               | Urokinase plasminogen activator (uPA), GSK-3β | –           | Urokinase plasminogen activator (uPA), GSK-3β | PI3K/AKT, ERK | Urokinase plasminogen activator (uPA) realized from cancer-associated fibroblasts (CAF) via the PI3K/AKT and ERK pathways can promote migration, invasion, and proliferation of ESCC cells | [53]  |
| Eca109, TE-1, EC109, HET-1A | –                               | RUNX2, PARP, Caspase-3, GSK-3β | –           | RUNX2, PARP, Caspase-3, GSK-3β | PI3K/AKT, ERK | Expression of RUNX2 by activating the PI3K/AKT and ERK pathways could play an oncogenic role in ESCC cells                                                                 | [54]  |
| KYSE-30                     | Aprepitant                       | 0–100 µM           | –           | NF-kB               | PI3K/AKT   | SP/NK1R system via the PI3K/Akt/NF-kB pathway could be involved in the pathogenesis of ESCC                                                             | [55]  |
Table 3 (continued)

| Samples | Cell lines                                      | Drug/phytotherapy | Dose range | Target                              | Pathway                          | Function                                                                 | Refs. |
|---------|-------------------------------------------------|-------------------|------------|-------------------------------------|----------------------------------|--------------------------------------------------------------------------|-------|
| –       | EC109, KYSE510, EC9706, NE2, COLO680N, SHEE, EC171, EC18, EC8712 | –                 | –          | mIR-200b, E-cadherin, Vimentin, ZEB1/2 | Kindlin-2/integrin β1/AKT       | mIR-200b via inhibiting the Kindlin-2-integrin β1/AKT pathway could decrease invasion of ESCC cells | [56]  |
| 145 pairs of ESCC and adjacent normal tissues | –                 | –                 | –          | PTEN, P70S6K1, 4E-BP1               | PI3K/AKT, mTOR                  | PTEN low expression and induction of PI3K/AKT/mTOR signaling can increase ESCC progression | [57]  |
| ESCC (n=68), | TE-8, TE-9, TE-15, Het-1A | –                 | –          | CCL3, CCR5/1, MMP2, MMP9, VEGFA    | PI3K/AKT, MEK/ERK               | CCL3–CCR5 axis via the MEK/ERK and PI3K/AKT pathways could promote invasion, migration, and angiogenesis of ESCC cells | [58]  |
| BALB/c nude mice | Eca109, TE-1 | –                 | –          | HPV16 E6-E7, p75NTR               | PI3K/AKT                        | HPV16 E6-E7 via up-regulating the p75NTR and activating the PI3K/AKT pathway could act as a cancer stem-like cells (CSCs) phenotypes promoter in ESCC cells | [59]  |
expression of autophagy-related proteins. Most notably, α-mangostin can inhibit activity of the PI3K/AKT/mTOR signaling, as demonstrated by down-regulation of p-PI3K, p-Akt and p-mTOR [115]. Moreover, Lapatinib could suppress epithelial-mesenchymal transition in skin SCC via modulation of WNT/ERK/PI3K/AKT axis [116]. The anti-cancer effects of Lactucopicrin in skin cancer is also mediated through modulation of PI3K/AKT/mTOR pathway [103].

A number of non-coding RNAs can also modulate progression of skin SCC through influencing activity of PI3K/AKT pathway. For instance, miR-451a via PDPK1-mediated PI3K/AKT signaling could prevent progression of skin SCC [117]. Moreover, IncRNA LINCO0520 via inactivating the PI3K/AKT pathway by down-regulating EGFR could prevent the progression of this type of cancer [118]. Table 7 shows the role of PI3K/AKT pathway in skin SCC. Figure 2 represents the role of several ncRNAs in various types of SCCs via regulating the PI3K/AKT/mTOR signaling pathway.
| Type of diseases | Samples | Cell lines | Drug/phytotherapy | Dose range | Target | Pathway | Function | Refs. |
|------------------|---------|------------|------------------|------------|--------|---------|----------|-------|
| Hypopharyngeal Squamous Cell Carcinoma (HPSCC) | HPSCC (n = 55) | FaDu | GDC-0980, Refametinib | 0–5 µM, 0–20 µM | cyclin D1, p27, pRb, p–PKCζ, p–Integrin β1 | PI3K/AKT, MAPK/ERK | GDC-0980 and refametinib via inhibiting the PI3K/AKT and MAPK/ERK pathways can suppress HPSCC cell proliferation, migration, and arrest cell cycle | [60] |
| HPSCC | 16 pairs of HPSCC and nearby non-cancerous tissues | FaDu | – | – | calcium-binding protein A11, S100A11, EGFR, CD44, MMP2/9, Bcl-2 | PI3K/AKT, mTOR | S100A11 via the PI3K/AKT pathway participates in the migration, carcinogenesis and protection of HPSCC from cell death induced by 5-Fu | [63] |
| HPSCC | 12 pairs of HPSCC and adjacent normal tissues, male BALB/cAnN.Cg nude mice | FaDu | NVP-BEZ235, Cisplatin | 50 nM, 2000 nM | 4E-PB1, Caspase 3, PARP | PI3K/AKT, mTOR | NVP-BEZ235 when combined with cisplatin could synergistically inhibit HPSCC cell proliferation and arrest cell cycle at G2/M phase via the PI3K/AKT/mTOR pathway | [61] |
| HPSCC | – | FaDu | – | – | JARID1B, K10, Flag, H3K4me3, β-catenin | SHIP1/AKT | JARID1B via the SHIP1/AKT pathway could improve HPSCC cell differentiation and suppress proliferation | [62] |
| HPSCC | 56 pairs of HPSCC and adjacent normal tissues, male nude mice | FaDu | – | – | Argonaute 2 (AGO2), p53, Caspase-3, FAK | PI3K/AKT | AGO2 via the FAK/PI3K/AKT pathway could increase tumor growth, proliferation, migration, and invasion of HPSCC cell | [64] |
| HPSCC | – | FaDu, 293 T | EGFRmAb–AuNPs | 20 mM | Bcl-2, Bax, Caspase-3/9 | PI3K/AKT, mTOR | Photothermal treatment with EGFRmAb–AuNPs via the PI3K/AKT/mTOR pathway and DNA destruction enhances apoptosis in HPSCC cells | [65] |
| Oropharyngeal Squamous Cell Carcinoma (OPSCC) | OPSCC (n = 116) | – | – | – | PTEN | AKT | HPV could activate the PI3K/AKT pathway and increase levels of pAKT (Ser473) and PTEN in OPSCC | [66] |
| Type of diseases                                      | Samples                  | Cell lines | Drug/phytotherapy | Dose range | Target      | Pathway         | Function                                                                                           | Refs. |
|------------------------------------------------------|--------------------------|------------|-------------------|------------|-------------|-----------------|----------------------------------------------------------------------------------------------------|-------|
| OPSCC                                                | OPSCC (n = 121)          | –          | –                 | –          | EGFR, PTEN  | AKT             | Because of HPV, level of PTEN, EGFR and pAKT, could be different between oropharyngeal and oral cavity squamous cell carcinoma | [67]  |
| Pharyngeal Squamous Cell Carcinoma (PSCC)            | –                        | NHOK, FaDu | Adenosine         | 0–3 mM     | Bax, Bcl-2, caspase-3/9 | PI3K/AKT, mTOR | Adenosine via the PI3K/AKT/mTOR pathway and activating caspase-3/9 could induce mitochondrial intrinsic apoptosis in PSCC cells | [68]  |
| Samples                          | Cell Lines              | Drug/phytotherapy | Dose range | Target                                      | Pathway             | Function                                                                 | Refs. |
|---------------------------------|-------------------------|-------------------|------------|---------------------------------------------|---------------------|---------------------------------------------------------------------------|-------|
| Male Balb/c nude mice           | CAL-27, SCC-9           | Lycopene          | 0–2 µM     | Bax, Bcl-2, E-cadherin, N-cadherin         | PI3K/AKT, mTOR, EMT | Lycopene by suppressing the EMT pathway and activating the PI3K/AKT/mTOR pathway could induce apoptosis and inhibit invasion, cell proliferation, and migration of OSCC cells | [69]  |
| –                               | KB, K562, MCF-7          | Thymoquinone (TQ) | 0–2 µM     | –                                           | PI3K/AKT            | TQ through suppression of the PI3K/AKT pathway could suppress invasion, proliferation, migration and induce apoptosis in OSCC cells | [70]  |
| TSCC (n= 72 patients)           | SCC4, SCC15, SCC25, Hs 680 | –                 | –          | LncRNA MALAT1, MMP-9                        | PI3K/AKT            | Suppression of lncRNA MALAT1 could inhibit invasion, migration, and proliferation of TSCC cells via suppressing the PI3K/AKT pathway and down-regulating MMP-9 | [72]  |
| 52 OSCC tissues with the        | CGHNNK2, SCC25, HSC3     | –                 | –          | FBXW7, miR-27a, Vimentin, N-cadherin, E-cadherin | PI3K/AKT            | Up-regulation of FBXW7 and downregulation of miR-27a via the PI3K/AKT pathway can suppress the proliferation and cell growth of OSCC | [74]  |
| corresponding non-tumor tissues |                         |                   |            |                                             |                     |                                                                           |       |
| OSCC (n=80), adjacent non-tumor | HUVEC, CAL27             | –                 | –          | miR-210-3p, EFNA3                          | PI3K/AKT            | miR-210-3p by increasing the phosphorylation rate of AKT could promote OSCC cells angiogenesis, migration, and proliferation | [75]  |
| tissues (n= 7)                  |                         |                   |            |                                             |                     |                                                                           |       |
| Datasets                        | H01-N-1, SCC-9, HNOEC   | –                 | –          | ITGA5, ERK                                 | PI3K/AKT            | ITGA5 via the PI3K/AKT pathway could play an oncogenic role and promote invasion, proliferation, and migration of OSCC cells | [76]  |
| 57 pairs of OSCC and adjacent   | Tca-8113, SCC-15, HOK    | –                 | –          | CircCDR1, HIF-1α, p62, LC3/VII, ATG5, Bax, Bcl-2, Caspase-3 | AKT, ERK1/2, mTOR   | CircCDR1 via the AKT/ERK/mTOR pathway could improve the viability of OSCC cells by promoting autophagy | [73]  |
| non-tumor tissues, female       |                         |                   |            |                                             |                     |                                                                           |       |
| BALB/c nude mice                |                         |                   |            |                                             |                     |                                                                           |       |
Table 5 (continued)

| Samples                          | Cell Lines   | Drug/phytotherapy | Dose range | Target                      | Pathway     | Function                                                                 | Refs. |
|----------------------------------|--------------|-------------------|------------|-----------------------------|-------------|--------------------------------------------------------------------------|-------|
| BALB/c nude mice                 | SCC4, CAL-27 | Licochalcone A    | 0–100 μM   | PCNA, MMP-2/9                | PI3K/AKT    | Licochalcone A could suppress OSCC cells migration, invasion, and proliferation via modulation of the PI3K/AKT pathway | [71]  |
| 98 paraffin embedded OSCC samples| HSC3, OSCC3, SCC4, SCC7, Cal27, HaCaT | –            | –          | SPARC, PDGFB, PDGFRβ        | PI3K/AKT    | SPARC via the PI3K/AKT/PDGFB/PDGFRβ axis could promote metastasis and proliferation of OSCC cells | [77]  |
| male Syrian hamsters             | SCC131, SCC4 | Astaxanthin (AXT), wortmannin, Bay-11, S31-201 | 0–1200 μM, 0–200 nM, 0–10 μM, 0–120 μM | NF-κB, Bcl-2, Bax, Cyclin-D1, p21, MMP-2/9, Caspase-3/9, HIF-1α, VEGF, VEGFR2 | PI3K, STAT3 | AXT in combination with wortmannin, Bay-11 or S31-201 via the PI3K/NF-κB/STAT3 axis could suppress apoptosis evasion, invasion, proliferation, and angiogenesis of OSCC cells | [78]  |
| 124 pairs of paraffin-embedded OSCC and adjacent tissues, female BALB/c nude mice | SCC15, SCC25 | –            | –          | TGF-β, SOX2, BMI1, ERK1/2, ABCG2, CD44, ML | AKT/FOXO3a | TGF-β via AKT/FOXO3a axis could induce stemness in OSCC | [76]  |
| 62 pairs of OSCC and adjacent non-tumor tissues, female BALB/c nude mice | SCC25, Cal27 | –            | –          | B7-H3, PFKFB3, Glut1         | PI3K/AKT, mTOR | Protein B7-H3 via the PI3K/AKT/mTOR pathway could increase tumor glucose uptake, aerobic glycolysis and metastasis in OSCC | [73]  |
| 20 pairs of OSCC and adjacent non-tumor tissues, athymic nude mice | SCC9, SCC15, SCC25, CAL27, hTERT-OME | Tanshinone IIA | 0–5 μM | HK2/1, VDAC1, Bax, GSX-3β, Caspase-3, PARP | AKT/c-Myc | Tanshinone IIA via the AKT/c-Myc pathway could inhibit OSCC by reducing of glycolysis | [74]  |
| TSCC (n=40)                      | Cal27, SCC9  | –            | –          | miR-21-5p, Bax, Bcl-2, PDCD4, FOXO1 | PI3K/AKT    | Downregulation of miR-21-5p by targeting PDCD4 that knockdown the PI3K/AKT/FOXO1 pathway could inhibit the invasion and proliferation of TSCC | [79]  |
| BALB/c nu/nu nude mice           | HOME-C, TSCCA, SCC15, CAL27 | –            | –          | Per2, LC3B, p62, Beclin-1    | PI3K/AKT, mTOR | Per2 via the PI3K/AKT/mTOR pathway can inhibit OSCC progression by activating autophagy | [80]  |
| Samples                                                                 | Cell Lines | Drug/phytotherapy | Dose range | Target                         | Pathway      | Function                                                                 | Refs. |
|------------------------------------------------------------------------|------------|-------------------|------------|--------------------------------|--------------|--------------------------------------------------------------------------|-------|
| 50 sample of OSCC and 10 of adjacent non-tumor tissues, female athymic | CAL27, HSC4, SCC15, 293 T | –                 | –          | USP13, GLUT1, HK2               | PTEN/AKT     | USP13 via regulating PTEN/AKT pathway act as a tumor suppressor          | [81]  |
| Male Balb/c-nude mice                                                 | TSCCa, Tca-8113 |                  |            | CCNS, Bax, Cyclin-D1/E, CDK2, Bcl-2, Procapase-3/9 | PI3K/AKT     | CCNS via the PI3K/AKT pathway can suppress proliferation and promote apoptosis of OSCC | [82]  |
| 116 pairs of OSCC and adjacent non-tumor tissues                       | SCC-25, HOK | –                 | –          | PAR-2                          | PI3K/AKT, mTOR| PAR-2 via the PI3K/AKT pathway could enhance invasion, migration, and proliferation of OSCC | [83]  |
| BALB/c nude mice                                                      | SCC-4, HSC3, CAL27, HN6, HOK | –                 | –          | TROP2, PTEN, PDK1               | PI3K/AKT     | TROP2 via PI3K/AKT could promote cell growth, migration, proliferation, and invasion in OSCC cells | [84]  |
| –                                                                     | OSC-4      | –                 | –          | GSK-3β, Rab-5B, Calnexin, Cytochrome-c | AKT          | Macrophage-derived exosomes by activating the AKT/GSK-3β pathway could reduce sensitivity to chemotherapeutic agents in OSCC cells | [85]  |
| OSCC (n=155)                                                           | OC3, OECM1, SCC4, SCC25, SAS, CGNHC9 | –                 | –          | Activin A, EGFR, SP1, Smad-2/3/4 | PI3K/SP1     | Activin A via activating the PI3K/SP1 pathway could regulate EGFR was necessary for the carcinogenesis of OSCC | [86]  |
| –                                                                     | SCC131     | Syringic acid (SRA) | 0–45 μm/mL | TNF-α, COX-2, iNOS, IL-6, VEGF, NF-κB | PI3K/AKT     | SRA via suppression of the PI3K/AKT/NF-κB axis could induce disruption of MMP, mitochondrial apoptosis, and inhibit cell proliferation and migration | [87]  |
| –                                                                     | SCC-25     | –                 | –          | Alpha-hederin (α-HN), Bax, Bcl-2 | PI3K/AKT, mTOR| α-HN via the PI3K/AKT/mTOR pathway can inhibit cell proliferation, adhesion, invasion and induce apoptosis of OSCC cells | [88]  |
| Samples | Cell Lines | Drug/phytotherapy | Dose range | Target | Pathway | Function | Refs. |
|---------|------------|-------------------|------------|--------|---------|----------|-------|
| OSCC (n = 53), BALB/C nude mice | Cal-27, SCC-25, HIOEC | – | – | miR-210-3p, EFNA3, N-cadherin, E-cadherin | PI3K/AKT | Up-regulation of miR-210-3p via the Ephrin-A3/PI3K/AKT pathway could inhibit OSCC cells development and metastasis | [89] |
| 162 OSCC samples with oral submucous fibrosis (OSF), 38 normal buccal mucosa (NBM) | CAL27, HN6, UM1, SCC9, HOK, 293 T | – | – | circEPSTI1, miR-942-5p, LTBP2, Vimentin, N-cadherin, E-cadherin | EMT, PI3K/AKT, mTOR | The circEPSTI1/miR-942-5p/LTBP2 axis via the EMT and PI3K/AKT/mTOR pathways could promote invasion, migration, and proliferation of OSCC cells | [90] |
| Male BALB/c nude m | NHOK, SCC-25, SCC-9 | Genipin | 0–400 μM | Survivin, PARP, Caspase-3, p62, Beclin-1, LC3II/LC3I | PI3K/AKT, mTOR | Genipin via the PI3K/AKT/mTOR pathway could induce autophagy and apoptosis and suppress the proliferation of OSCC cells | [91] |
| – | CAL-27, SCC-25 | Pristimerin, 5-fluorouracil, cisplatin | 0–1 μM, 0–150 μM, 0–20 μM | p21, p27, p53 PARP, Caspase-3 | AKT, MAPK/ERK | Pristimerin via the MAPK/ERK1/2 and AKT pathways could induce apoptosis and suppress proliferation of OSCC cells more than cisplatin and 5-fluorouracil | [92] |
| – | HOEC, HN4, HN30, HN6 | – | – | PLAC8, PCNA, c-Myc, GSK-3β, Cyclin-D1, E-cadherin, Vimentin | Wnt/β-catenin, PI3K/AKT | PLAC8 via the PI3K/AKT/GSK-3β and Wnt/β-catenin pathways could inhibit carcinogenesis and EMT of OSCC cells | [93] |
| Cohort, BALB/c nu/nu female nude mice | SCC15, CAL27, HOMEC, TSCCA | – | – | IncRNA CASC9, p62, Bcl-2, Bax, LC3II/LC3I | AKT/mTOR | IncRNA CASC9 via the AKT/mTOR pathway can promote tumoral cell proliferation and progression by suppressing autophagy in OSCC | [94] |
| 86 sample of OSCC and 32 sample of adjacent non-tumor tissues, SPF-grade BALB/c nu/nu female nude mice | HOMEC, TSCCA, SCC15, CAL27 | – | – | Perl1, LC3BII/I, Beclin-1, P62, Bax | AKT/mTOR | Clock gene Perl1 via the AKT/mTOR pathway could suppress autophagy and improve cell proliferation in OSCC | [95] |
| Samples                  | Cell Lines                         | Drug/phytotherapy | Dose range | Target                                      | Pathway       | Function                                                                 | Refs. |
|-------------------------|------------------------------------|-------------------|------------|---------------------------------------------|---------------|--------------------------------------------------------------------------|-------|
| OSCC (n = 92)           | SCC4, Cal27, H5C3, HaCaT           | –                 | –          | LGALS3BP                                    | P13K/AKT      | LGALS3BP via the P13K/AKT pathway could promote migration and proliferation of OSCC cells | [96]  |
| –                       | CAL27, SCC9                         | –                 | –          | Notch1, N-cadherin, Vimentin, E-cadherin, β-catenin, P21, Cyclin-D3 | EGFR, P13K/AKT | Membrane-tethered Notch1 via activating the EGFR/P13K/AKT axis could exhibit oncogenic property in OSCC | [97]  |
| BALB/cnu/nu nude mice   | Ca127                              | –                 | –          | miR-134, LAMC2, GSK-3β, Caspase-9, Bcl-2, Bax | P13K/AKT      | miR-134 by down-regulating LAMC2 via the P13K/AKT pathway can suppress cell migration, invasion, and metastases of OSCC cells | [98]  |
| OSCC (n = 134)          | SNU1041, SCC25, SCC4, SCC9, hNOK   | –                 | –          | lncRNA FTH1P3, GSK-3β                        | P13K/AKT, Wnt/β-catenin | LncRNA FTH1P3 via the P13K/AKT/GSK-3β/ Wnt/β-catenin axis could promote migration and invasion in OSCC cells | [99]  |
| 8 pairs of OSCC and adjacent normal tissue | SCC-9, TEC, SCC-25, TSCCa, Tca-8113 | –                 | –          | miR-194, FoxO3a, Cyclin-D1, p21, AKK         | P13K/AKT      | miR-194 by reducing the P13K/AKT/FoxO3a axis could inhibit cell proliferation of OSCC | [100] |
| OSCC (n = 125)          | –                                  | –                 | –          | PTEN                                         | P13K/AKT, mTOR | Activity of P13K/AKT pathway is enhanced in the gingival, hard palate, and alveolar ridge SCC. The expression of p-mTOR could be considered as a biomarker of survival in OSCC | [101] |
| 8 pairs of OSCC and normal oral mucosal tissue | –                                  | –                 | –          | c-Met                                        | P13K/AKT      | Carcinoma associated fibroblasts (CAF) via the c-Met/P13K/AKT pathway could induce lymphangiogenesis in OSCC | [102] |
| Samples | Cell Lines | Drug/phytotherapy | Dose range | Target | Pathway | Function | Refs. |
|---------|------------|-------------------|------------|--------|---------|----------|-------|
| OSCC (n=56), BALB/c-nude mice | CAL27, SCC9, HCT 116, 293 T | Cisplatin | 0–35 µg/mL | miR-22, KAT6B, Caspase-3, PARP, p53, Bcl-2, NF-kB | PI3K/AKT | Overexpression of miR-22 and suppression of KAT6B via the PI3K/AKT/NF-kB pathway can increase the OSCC cells apoptosis by enhancement of the sensitivity of these cells to cisplatin | [103] |
| – | KB | Sanguinarine | 0–2 µM | Caspase-3/8/9, Fas/Fasl, Bid, Bax, Bcl-2, TRAIL | PI3K/AKT | Sanguinarine via suppressing the PI3K/AKT pathway could induce apoptosis of OSCC cells | [104] |
| Paraffin-embedded OSCC (n=90) | SCC25, 1483, FeOSCC, K9OSCC | doxorubicin, AD198 | 0–1 µM, 0–1 µM | cPARP, ERK1/2, p38, GSK-3β, Caspase-3/7 | PI3K/AKT | Dox or AD198 as an anthracycline therapy via inhibiting the PI3K/AKT can inhibit cell proliferation in OSCC cells | [106] |
| OSCC (n=12), male nude BALB/c mice | SCC4, SCC25, OML1, OML1-R | – | – | Bax, Caspase-3, Cyclin-D1, CDK4 | PI3K/AKT, mTOR | The PI3K/mTOR pathway is involved in sensitizing OSCC cells to radiotherapy | [107] |
| OSCC (n=25), adjacent non-tumor tissues (n=5), nude mice | Tca-8113, KB | – | – | Zinc Finger Protein 703, c-Myc, GSK-3β, Vimentin, Snail, N-cadherin, E-cadherin | PI3K/AKT | Zinc Finger Protein 703 via PI3K/AKT/GSK-3β pathway could promote metastasis and cell proliferation of OSCC | [108] |
| 60 pairs of OSCC and adjacent normal tissue | SCC-25, HSC3 | – | – | Cyclin-D1, T-cadherin | PI3K/AKT, mTOR | T-cadherin via inhibiting the PI3K/AKT/mTOR pathway could suppress the proliferation of OSCC | [109] |
| Samples | Cell Lines | Drug/phytotherapy | Dose range | Target | Pathway | Function | Refs. |
|---------|------------|-------------------|------------|--------|---------|----------|-------|
| Male Syrian hamsters | Cal27, LN4, Leuk1 | Salvanic acid B | 0–600 µM | GLUT1, HIF-1α | PI3K/AKT | Salvanic acid B via the PI3K/AKT/HIF-1α axis could suppress OSCC malignant transformation by inhibiting aberrant glucose metabolism | [110] |
| 58 pairs of TSCC and adjacent normal tissue | SCC9, SCC25 | – | – | FoxM1, E-cadherin, Vimentin | c-Met/AKT | FoxM1 via the c-Met/AKT-dependent positive feedback loop pathway could promote EMT, migration, and invasion of TSCC | [111] |
| female BALB/c nude mice | SCC-25, UM1, UM2, HSC-3, Cal27 | Oridonin | 0–10 mg/kg | Bcl-2, Bax, Caspase-3/9, Cyclin-D1/D3, p21 | PI3K/AKT | Oridonin through suppression the PI3K/AKT pathway could suppress proliferation and induce apoptosis and G2/M-phase arrest in OSCC cells | [112] |
| – | SCC25 | Plumbagin (PLB) | 0–5 µM | Bax, Bcl-2, Caspase-3/9, GSK-3β, Beclin-1, LC3-I/II | p38 MAPK, PI3K/AKT, mTOR | Plumbagin via MAPK and PI3K/AKT/mTOR-mediated pathways could promote autophagy, G2/M arrest, apoptosis, and increase intracellular levels of ROS in TSCC cells | [113] |
| Female BALB/c mice, 36 pairs of OSCC tissues and adjacent normal tissues | TSC-15, CAL27, TSCCa, Tca8113, SCC-4, SCC-25 | – | – | PON3, AP-1 | PI3K/AKT | PON3 via the PI3K/AKT pathway can promote migration, invasion, and cell proliferation in OSCC cells | [114] |
Table 6  Role of PI3K/AKT pathway in head and neck squamous cell carcinoma

| Samples                                                                 | Cell Lines                          | Drug/phytotherapy  | Dose range | Target                        | Pathway          | Function                                                                 | Refs. |
|------------------------------------------------------------------------|-------------------------------------|--------------------|------------|--------------------------------|------------------|--------------------------------------------------------------------------|-------|
| -                                                                      | SCC-4, SCC-9, SCC-25, FaDu, UM-SCC-22A | Chloroquine (CQ)   | 0–30 µM    | MAP1LC3B, SQSTM1                | PI3K/AKT, mTOR   | PI3K/AKT/mTOR autophagy pathway could be blocked by CQ that had an inhibitory effect on HNSCC proliferation | [43]  |
| 114 pairs of HNSCC and adjacent normal tissues                        | FaDu, Cal-27, SCC4, SCC9, HaCaT     | –                  | –          | RNA FKBP9P1                     | PI3K/AKT         | Silencing expression of RNA FKBP9P1 via PI3K/AKT signaling pathway can constrain the progression of HNSCC | [38]  |
| –                                                                      | Fadu, SSC-9, SSC-25, OSC-19, Cal-27, HOK | –                  | –          | Profilin 2 (PFN-2), GSK-3β, β-catenin | PI3K/AKT         | PFN2 via activating the PI3K/AKT/β-catenin pathway could promote the proliferation and metastasis of HNSCC | [39]  |
| –                                                                      | FaDu, Ca127, SCC25, HN4             | Osthole            | 0–240 µM   | PTEN, Gdc-2, Cyclin-B1, Bcl-2, Bax, PARP1, Survivin, Caspase3/9 | PI3K/AKT         | Osthole via suppressing the PI3K/AKT pathway could have an anti-tumor effect on HNSCC | [41]  |
| Male BALB/cAJcl-nu/nu nude mice                                        | HSC-3 shDKK3, HSC-3 shScr           | –                  | –          | DKK3, β-catenin, GSK-3β, p53, PDK1, p38, TGF-β | PI3K/AKT, mTOR, MAPK | DKK3 via the PI3K/AKT/mTOR and MAPK pathways could increase the malignant properties of HNSCC | [40]  |
| Female BALB/C nude, HNSCC (n=298), NCLM (n=98)                       | FaDu, 293 T, AMC-HN-8, Tca-8113, Cal-27 | –                  | –          | STC2, Snail, Vimentin, E-cadherin | PI3K/AKT         | STC2 via the PI3K/AKT/Snail pathway can promote HNSCC metastasis, proliferation, and tumoral cell growths | [44]  |
| –                                                                      | OSC-20, HEC, SNU-1076, HSC-3, Ca9-22 | –                  | –          | HPIP                           | PI3K/AKT         | Knockdown of HPIP via suppressing the PI3K/AKT pathway could inhibit invasion, proliferation, and invasion of HNSCC | [45]  |
| HNSCC (n=36), Female C57BL/6 mice                                     | PBMC, TIL                           | –                  | –          | Tim-3                          | PI3K/AKT         | Adaptive resistance to anti-programmed death-1 (PD1) therapy through up-regulating Tim-3 could be mediated via the PI3K/AKT pathway | [42]  |
| HNSCC (n=36)                                                          | Tu686, 5-8F                          | –                  | –          | Metadherin (MTDH), VEGF        | PI3K/AKT         | MTDH could regulate VEGF expression via the PI3K/AKT pathway, resulting in HNSCC metastasis and angiogenesis | [46]  |
Table 7  Role of PI3K/AKT pathway in cutaneous squamous cell carcinoma

| Type of Diseases | Samples | Cell Lines | Drug/phytotherapy | Dose range | Target | Pathway | Function | Refs. |
|------------------|---------|------------|-------------------|------------|--------|---------|----------|-------|
| Skin cancer      | Female ICR mice | – | a-mangostin | 5 and 20 mg/kg | IL-4/10/18, IL-1, Bax, Caspase-3, Bcl2, LC3-I/II, Beclin-1 | PI3K/AKT, mTOR | a-Mangostin by regulating PI3K/AKT/mTOR pathway could inhibit DMBA/TPA-induced skin cancer | [115] |
| Cutaneous squamous cell carcinoma (CSCC) | – | SCC, A431 | Lapatinib | 0–5 μM | Caspase-8, Bcl-2, EGFR, N-cadherin, Vimentin | WNT/β-catenin, PI3K/AKT, mTOR, ERK1/2 | Lapatinib via the WNT/ERK/PI3K/AKT axis could suppress EMT | [116] |
| Skin cancer      | – | SKMEL-5 | Lactucopicrin | 0–30 μM | Bax, Bcl-2 | PI3K/AKT, mTOR | Lactucopicrin via inhibiting the PI3K/AKT/mTOR pathway exerted anticancer effects on skin cancer cells | [103] |
| Skin carcinoma   | – | A549, A431, PaCa-2, PC-3, MCF-7, SNU-5, HTB-39 | caffeic acid n-butyl ester (CAE) | 0–40 μM | Bax, Bcl-2 | PI3K/AKT, mTOR | CAE via induction of apoptosis and inhibition of the PI3K/AKT/mTOR pathway could reduce proliferation of skin cancer cells | [119] |
| CSCC             | – | HaCaT, cSCC, A431, HSC-5, SCC-12, SCL-1 | – | – | miR-451a, PDPK1 | PI3K/AKT | miR-451a via PDPK1-mediated PI3K/AKT modulation could prevent CSCC progression | [117] |
| CSCC             | Female nude mice | cSCC, A431 | – | – | LINC00520, EGFR, VEGF, MMP-2/9 | PI3K/AKT | IncRNA LINC00520 via inactivating the PI3K/AKT pathway by decreasing EGFR could prevent the progression of CSCC | [118] |
| CSCC             | CSCC tissues (n=11), normal skin tissues (n=4) | cSCC, NHEK HaCaT, A431, SCL-1 | – | – | Kynureninase (KYNU) | PI3K/AKT | Downregulation of KYNU could restrain CSCC proliferation and repress the PI3K/AKT pathway | [120] |
| CSCC             | – | SCC13, A431 | High mobility group box 1 (HMGB1) | 0–100 ng/mL | p42/44, p38 | PI3K/AKT, MAPK | HMGB1 via the PI3K/AKT and MAPK pathways can influence tumor metastasis | [121] |
Discussion

PI3K/AKT has essential roles in the development of different types of SCC. Over-expression of PI3K, AKT, and p-mTOR has been reported in SCC tumors in association with down-regulation or absence of PTEN [122]. Gain of function mutations in constituents of this pathway, amplification of PIK3CA and AKT, overexpression of AKT and inactivating mutations or loss of PTEN are involved in the aberrant activity of this signaling pathway and subsequent progression of cancer [Simpson, 2015 #155]. Thus, identification of the underlying mechanism of over-activation of PI3K/AKT pathway in SCC has practical significance in design of novel therapeutic options.

Moreover, a number of anti-cancer drugs such as cisplatin, LY294002, Licochalcone A, Mukonal, Dehydrocostus Lactone, Curcumin, Chloroquine, Osthole, Vitamin E succinate, Dasatinib, Tan shinone IIA, Genipin, Pristimerin, 5 fluorouracil, Sanguinarine, doxorubicin, AD198, Salvanic acid B, Oridonin, Plumbagin,
a-mangostin, Lapatinitb, Lactucopicrin and caffeine acid n-butyl ester have been found to exert their therapeutic effects in SCC via modulation of this pathway. It is worth mentioning that drug-loaded nanospheres and microspheres as a novel strategy for drug delivery can be used to form a material, mechanism, and cell combination that can not only treat the disease, but also verify the pathway. The possibility of using these systems for delivery of aforementioned drugs should be studied in future studies.

In brief, the bulk of evidence shows the impact of dysregulation of PI3K/AKT pathway in the pathogenesis of SCC and determination of survival of patients with this type of cancer. Moreover, targeted therapies against this pathway have been found to be effective in reduction of tumor burden both in animal models and clinical settings. Since this pathway has an established role in the induction of epithelial-mesenchymal transition, these therapies are expected to affect tumor metastasis as well. Besides, therapeutic modalities against PI3K/AKT might act in a synergic manner with other anticancer modalities, enhancing the survival of affected individuals. PI3K/AKT pathway can also act as a mediator of HPV-induced cancer stem-like cells features in SCC [59], further highlighting the importance of this pathway in malignant features of SCC.

Finally, a number of molecules that regulate PI3K/AKT pathway can be used as diagnostic markers for different types of SCCs.

Recent studies have also indicated the impact on non-coding RNAs in the regulation of PI3K/AKT pathway in different cancers, including SCC [123]. Thus, when designing novel therapeutic options against this pathway, it is necessary to consider the regulatory roles of these transcripts and their expression levels in these patients. Such approach may lead to establishment of a more effective personalized therapeutic strategy.

Acknowledgements

The authors would like to thank the clinical Research Development Unit (CRDU) of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran for their support, cooperation and assistance throughout the period of study (Grant Number 43002643).

Author contributions

SGF wrote the manuscript and revised it. MT and EJ supervised and designed the study. TK, AA and BMH collected the data and designed the figures and tables. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent forms were obtained from all study participants. The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences. All methods were performed in accordance with the relevant guidelines and regulations.

Consent of publication

Not applicable.

Competing interests

The authors declare they have no conflict of interest.

Author details

1 Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2 Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran. 3 Department of Pharmacology, Tabriz University of Medical Sciences, Tabriz, Iran. 4 Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5 Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq. 6 Center of Research and Strategic Studies, Lebanese French University, Kurdistan Region, Erbil, Iraq. 7 Institute of Human Genetics, Jena University Hospital, Jena, Germany. 8 Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 9 Department of Pathology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 5 February 2022   Accepted: 5 August 2022

Published online: 13 August 2022

References

1. Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587–629.
2. Fayard E, Moncayo G, Hemmings BA, Holländer GA. Phosphatidylinositol-3-kinase signaling in thymocytes the need for stringent control. Sci Signal. 2010;3(135):res5-re.
3. Fruhan DA, Limon JJ. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012;3:228.
4. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15(25):6341–51.
5. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTORC complex. Science. 2005;307(5712):1098–101.
6. Hou M-M, Liu X, Wheler J, Naing A, Hong D, Coleman RL, et al. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: a phase I clinical experience. Oncotarget. 2014;5(22):11166–79.
7. Srinivas KP, Viji R, Dan VM, Sajitha IS, Prakash R, Rahul PV, et al. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. Oncotarget. 2016;7(17):24154–71.
8. Li R, Song Y, Zhou L, Li W, Zhu X. Downregulation of RAGE inhibits cell proliferation and induces apoptosis via regulation of PI3K/AKT pathway in cervical squamous cell carcinoma. Oncotargets Ther. 2020;13:2385.
9. Prasad SR, Yadav SS, Das M, Modi A, Kumari S, Pandey LR, et al. PI3K/AKT pathway-mediated regulation of p27Kip1 is associated with cell cycle arrest and apoptosis in cervical cancer. Cell Oncol. 2015;38(3):215–25.
10. Zhang D, Sun G, Zhang H, Tian J, Li Y. Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways. BioMed Pharmacother. 2017;85:511–6.
11. Wang C, Gu W, Zhang Y, Ji Y, Wen Y, Xu X. Nicotine promotes cervical carcinoma cell line HeLa migration and invasion by activating PI3K/Akt/ NF-kB pathway in vitro. Exp Toxicol Pathol. 2017;69(6):402–7.

12. Shu X-R, Wu J, Sun H, Chi L-Q, Wang J-H. PI4K confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway. Diagn Pathol. 2015;10(1):177.

13. Feng T, Zheng L, Liu F, Xu X, Mao S, Wang X, et al. Growth factor protein-granulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway. Oncotarget. 2016;173(36):5981–91.

14. Huang L, Huang Z, Fan Y, He L, Ye M, Shi K, et al. FOXC1 promotes proliferation of cervical epithelial-mesenchymal transition in cervical carcinoma through the PI3K-AKT signal pathway. Am J Transl Res. 2017;9(3):1297–306.

15. Zhang W, Zhou Q, Wei Y, Da M, Zhang C, Zhang J, et al. The exosome-mediated PI3K/Akt/mTOR signaling pathway in cervical cancer. Int J Clin Exp Pathol. 2019;12(7):2474–84.

16. Tao J-P, Lee C-Y, Ying T-H, Lin C-L, Lin C-L, Hsuwe J-T, et al. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. Oncotarget. 2015;6(30):30855–66.

17. Li A, Gu Y, Li X, Sun H, Zha H, Xie J, et al. S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3K/Akt signaling pathway. Onco Targets Ther. 2016;9(1):2289–95.

18. Xu X, Shu X-R, Zhang Y, Liu L. MicroRNA-433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling targeting by FAK. Oncol Rep. 2018;40(4):3469–76.

19. Lu R, Yang Z, Xu G, Yu S. miR-338 modulates proliferation and autophagy by PI3K/Akt/mTOR signaling pathway in cervical cancer. Biomed Pharmacother. 2018;105:63–44.

20. Li L, Huizhi L, Binu W, Xinxin D, Longjun W, Liping Y, et al. Anticancer proteins of HPV16 E6 and E7 inhibit the PI3K/Akt/mTOR pathway. Exp Pathol. 2019;12(7):2474–84.

21. Zhang R, Hao J, Wu Q, Guo K, Wang C, Zhang WK, et al. Dehydrocorticosterone lactone inhibits cell proliferation and induces apoptosis by PI3K/Akt/Bad and ERK signaling pathway in human cervical carcinoma. J Cell Mol Med. 2020;24(11):6028–42.

22. Starika K, Forma E, Lewy-Trenda I, Staskowska-Kanicka Q, Skóra M, Bryl M. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/Akt kinase activity, as well as invasion and progression, in human cervical cancer. Cell Oncol. 2018;41(3):253–68.

23. Zhao A, Tian L, Zhao B, Sun Y, Cao J, Chen K, et al. FADS1 promotes the progression of laryngeal squamous cell carcinoma through autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. Oncotarget. 2015;6(30):30855–66.

24. Gao W, Guo H, Niu M, Zhang X, Zhang Y, Xue X, et al. Autophagy plays an important role in the proliferation and invasion of cervical cancer cells. Cell Death Dis. 2020;11(4):1–14.

25. Gao W, Guo H, Niu M, Zhang X, Zhang Y, Xue X, et al. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PI3K-CaMKII signaling pathway. Mol Cancer. 2020;19(1):1–22.

26. Gao W, Zhang Y, Luo H, Niu M, Zeng X, Xue X, et al. Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous carcinoma via impairing PKL1-AKT axis-mediated glycolysis. Cell Death Dis. 2020;11(10):1–19.

27. Tang T, Xiao Z-Y, Shan G, Lei H-B. Descending-SHIP2-mediated radiosensitivity enhancement through PI3K/Akt signaling pathway in laryngeal squamous cell carcinoma. Biomed Pharmacother. 2019;118:109952.

28. Ye D, Zhou C, Deng H, Lin L, Zhou S. MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway. Cancer Manag Res. 2019;11:3801.

29. Zhu Y, Yan L, Zhu W, Song X, Yang G, Wang S. MMP2/3 promote the growth and migration of laryngeal squamous cell carcinoma via PI3K/AKT-NF-kB-mediated epithelial–mesenchymal transformation. J Cell Physiol. 2019;234(9):7547–55.

30. Tian L, Tao Z, Ye H, Li G, Zhan Z, Tuo H. Over-expression of MEOX2 promotes apoptosis through inhibiting the PI3K/Akt pathway in laryngeal cancer cells. Neoplasma. 2018;65(5):745–52.

31. Ni H, Hu SQ, Chen X, Liu YF, Ni TT, Cheng L. Tra2β silencing suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting PI3K/Akt signaling pathway. Oncol Lett. 2019;20(9):2909–2911.

32. Zhu X, Zhu R. Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway. Oncotarget. 2018;11:3521.
et al. Cancer Cell International          (2022) 22:254
56. Zhang H-F, Alshareef A, Wu C, Li S, Jiao J-W, Cao H-H, et al. Loss of
57. Wu N, Du Z, Zhu Y, Song Y, Pang L, Chen Z. The expression and prog‑
59. Xi R, Pan S, Chen X, Hui B, Zhang L, Fu S, et al. HPV16 E6–E7 induces
62. Zhang J, An X, Han Y, Ma R, Yang K, Zhang L, et al. Overexpression
63. Wang C, Lin C, Tao Q, Zhao S, Liu H, Li L. Evaluation of calcium‑binding
64. Zhang Y, Wang B, Chen X, Li W, Dong P. AGO2 involves the malignant
66. Horn D, Freudlsperger C, Holzinger D, Kunzmann K, Plinkert P, Dyckhoff
68. Choi MS, Moon SM, Lee SA, Park BR, Kim JS, Kim DK, et al. Adeno‑
2015;575:38–45.
(ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. Arch
Biochem Biophys. 2015;575:38–45.
pathway. J Cancer. 2019;10(23):5770.
regulated by miR‑27a through PI3K/AKT signaling pathway and epitelial‑to‑mesenchymal transition in oral squamous cell carcinoma. Eur
Med Pharmacol Sci. 2020;74(7):3701‑9.
pathway. Arch Oral Biol. 2019;101:85‑91.
expression inhibition suppresses tongue squamous cell carcinoma proliferation, migration and invasion by inactivating PI3K/AKT pathway
and downregulating MMP‑9 expression. Eur Rev Med Pharmacol Sci.
2019;23(1):198–206.
upregulation of pAKT (Ser473) expression in progression of oral squamous cell carcinoma. Oral Oncol. 2012;48(10):985–90.
regulated with EGFRmAb–AuNPs induces apoptosis in hypopharyngeal carcinoma cells via PI3K/Akt/mTOR signaling pathway. J Mol Med.
2019;2019(11):3655.
77. Jing Y, Jin Y, Wang Y, Chen S, Zhang X, Song Y, et al. SPARC promotes
78. Kowshik J, Nivetha R, Ranjan S, Venkatesan P, Selynuthukumar S, Veer‑
avarmal V, et al. Antaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF‑κB/STAT3 signaling axis in oral squamous cell carcinoma models. IJMBL Life. 2019;7(11):1595‑610.
79. Liu C, Tong Z, Tan J, Xin Z, Wang Z, Tian L. MicroRNA‑21‑5p targeting
PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma. Exp Ther Med.
2019;18(5):3543‑51.
81. Qu Z, Zhang R, Su M, Liu W. USP13 serves as a tumor suppressor via the
PTEN/AKT pathway in oral squamous cell carcinoma. Cancer Manag
Res. 2019;11:9175.
82. Guo L, Yang G, Kang Y, Li S, Duan R, Shen L, et al. Construction and
analysis of a ceRNA network reveals potential prognostic markers in colorectal cancer. Front Genet. 2020;11:1418.
83. Tang K-L, Tang H-Y, Du Y, Tian T, Xiong S‑J. PAR‑2 promotes cell prolifera‑
tion, migration, and invasion through activating PI3K/AKT signaling pathway in oral squamous cell carcinoma. 2019. Biosci Rep. https://doi.
84. Tang G, Tang Q, Jia L, Chen Y, Lin L, Kui X, et al. TROP2 increases
growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway. J Cell Mol Med.
2019;2019(4):6489‑96.
86. Tomita R, Sasabe E, Tomomura A, Yamamoto T. Macrophage‑derived
exosomes attenuate the susceptibility of oral squamous cell carcinoma
exosomes to oral squamous cell carcinoma cells by chemotherapeutic drugs through the AKT/GSK‑3β pathway. Oncol Rep. 2020;44(5):1905‑16.
87. Tsai C‑N, Tsai C‑L, Yi J‑S, Kao H‑K, Huang Y, Wang C‑I, et al. Activin A regulates the epithelial growth factor receptor promoter by activating the PI3K/Sp1 pathway in oral squamous cell carcinoma cells. Sci Rep. 2019;9(1):1‑14.
88. Velu P, Vayyalakshmi A, Vinothkumari V. Inhibiting the PI3K/Akt, NF‑κB
signalling pathways with syringic acid for attenuating the development of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway. Electron J Biotechnol. 2019;38:27‑31.
89. Wang L, Song Y, Wang H, Liu S, Shao Z, Zhang Z. MiR‑210‑3p‑EphrinA3‑Pi3K/AKT axis regulates the progression of oral cancer. J Cell Mol Med.
2020;24(7):4011‑22.
90. Wang J, Jiang C, Li N, Wang F, Xu Y, Shen Z, et al. The circEPSTI1/miR-942-5p/LTB2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway. Cell Death Dis. 2020;11(8):1–18.

91. Wei M, Wu Y, Liu H, Xie C. Genipin induces autophagy and suppresses cell growth of oral squamous cell carcinoma via PI3K/AKT/mTOR pathway. Drug Des Dev Ther. 2020;14:395.

92. Wu H, Li L, Ai Z, Yin J, Chen C. Pristimerin induces apoptosis of oral squamous cell carcinoma via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition. Oncol Lett. 2019;17(3):3017–25.

93. Wu J, Wang X, Shang A, Vella G, Sun Z, J-P, et al. PLAC8 inhibits oral squamous cell carcinogenesis and epithelial-mesenchymal transition via the Wnt/beta-catenin and PI3K/Akt/GSK3β signaling pathways. Oncol Lett. 2020;20(5):1.

94. Yang Y, Chen D, Liu H, Yang K. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the Akt/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10(2):1–16.

95. Yang G, Yang Y, Tang H, Yang K. Loss of the clock gene Per1 promotes oral squamous cell carcinoma progression via the Akt/mTOR pathway. Cancer Sci. 2020;111(5):1542.

96. Zhang X, Ding H, Lu Z, Ding L, Song Y, Jing Y, et al. Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway. Cell Signal. 2019;63:109359.

97. Zheng Y, Wang Z, Xiong Z, Zhong Y, Zhang W, Dong Y, et al. Membrane-tethered Notch1 exhibits oncogenic property via activation of EGFR-PI3K-AKT pathway in oral squamous cell carcinoma. J Cell Physiol. 2019;234(5):5940–52.

98. Zhou Y-M, Yao Y-L, Liu W, Shen X-M, Shi L-J, Wu L. MicroRNA-134 inhibits tumor stem cell migration and invasion in oral squamous cell carcinoma via downregulation of PI3K/Akt signaling pathway by inhibiting LAMC2 expression. Cancer Biomark. 2020. https://doi.org/10.3233/CBM-191362.

99. Liu M, Gao X, Liu C. Increased expression of IncRNA FTH1P3 promotes oral squamous cell carcinoma cells migration and invasion by enhancing PI3K/Akt/GSK3β/Wnt/beta-catenin signaling. Eur Rev Med Pharmacol Sci. 2018;22(3):8306–14.

100. Chi H. mirt-194 regulated AGK and inhibited cellular proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signaling. Biomed Pharmacother. 2015;71:53–7.

101. Ferreira DM, Neves TJ, Lima LGC, Alves FA, Begnami MD. Prognostic implications of the phosphatidylinositol 3-kinase/AKT pathway in oral squamous cell carcinoma: overexpression of p-mTOR indicates an adverse prognosis. Appl Cancer Res. 2017;37(1):1–8.

102. Gao P, Li C, Chang Z, Wang X, Xuan M. Carcinoma associated fibroblasts derived from oral squamous cell carcinoma promote lymphangiogenesis via c-Met/PI3K/AKT in vitro. Oncol Lett. 2018;15(1):331–7.

103. Gui Y, Liu H, Kong F, Ye J, Jia X, Zhang Z, et al. mirt-22/KAT6B axis is a chemotherapeutic determinant via regulation of PI3K-AKT-NF-κB pathway in tongue squamous cell carcinoma. J Exp Clin Cancer Res. 2018;37(1):1–14.

104. Lee TK, Park C, Jeong SJ, Jeong MJ, Kim GY, Kim WJ, et al. Sanguinarine induces apoptosis of human oral squamous cell carcinoma KB cells via inactivation of the PI3K/Akt signaling pathway. Drug Resist Updat. 2016;17(75):227–40.

105. Matsuo FS, Andrade MF, Loyola AM, da Silva SJ, Silva MB, Cardoso SV, et al. Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients. Virchows Arch. 2018;472(6):983–97.

106. Smoleński D, Rathore K, Bourn J, Cekanova M. Inhibition of the PI3K/AKT pathway sensitizes oral squamous cell carcinoma cells to anthracycline-based chemotherapy in vitro. J Cell Biochem. 2017;118(9):2615–24.

107. Yu C-C, Hung S-K, Lin H-Y, Chou W-Y, Lee M-S, Liao H-F, et al. Targeting the PI3K/AKT/mTOR signalling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo. Oncotarget. 2017;8(40):68641.

108. Wang H, Deng X, Zhang J, Chu Z, Mai J, Ding S, et al. Elevated expression of zinc finger protein 703 promotes cell proliferation and metastasis through PI3K/AKT/GSK3β signalling in oral squamous cell carcinoma. Cell Physiol Biochem. 2017;44(3):920–34.

109. Wang Q, Zhang X, Song X, Zhang L. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway. Arch Oral Biol. 2018;96:74–9.

110. Wei J, Wu J, Xu W, Nie H, Zhou R, Wang R, et al. Salvinianolic acid B inhibits polyglutamylation of oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1α signaling pathway. Cell Death Dis. 2018;9(6):1–16.

111. Yang H, Wen L, Wen M, Liu T, Zhao L, Wu B, et al. FoxM1 promotes epithelial–mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop. Anticancer Drugs. 2018;29(3):216.

112. Yang J, Ren X, Zhang L, Li Y, Cheng B, Xia J. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. Biomed Pharmacother. 2018;100:226–32.

113. Pan S-T, Qin Y, Zhou Z-W, He Z-X, Zhang X, Yang T, et al. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells. Drug Des Ther. 2015;9:1601.

114. Zhu L, Shen Y, Sun W. Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma. Biomed Pharmacother. 2017;85:712–7.

115. Wang F, Ma H, Liu Z, Huang W, Xu X, Zhang X. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice. Biomed Pharmacother. 2017;92:672–80.

116. Yao M, Shang Y-Y, Zhou Z-W, Yang Y-X, Wu Y-S, Guan L-F, et al. The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/EfK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. J Cancer. 2017;8(2):220.

117. Fu J, Zhao J, Zhang H, Fan X, Geng W, Qiao S. MicroRNA-451a prevents cutaneous squamous carcinoma progression via the 3-phosphoinositide-dependent protein kinase-1-mediated PI3K/AKT signaling pathway. Exp Therapeutic Med. 2021;21(2):1.

118. Mei X-L, Zhong S. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/AKT signaling pathway by downregulating EGFR. Chin Med J. 2019;132(4):454.

119. Zeng N, Hongbo T, Xu Y, Wu Y. Anticancer activity of caffeic acid n-butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/Pi3K/Akt signaling pathway. Mol Med Rep. 2018;17(4):5652–7.

120. Ci C, Wu C, Lyu D, Chang X, He C, Liu W, et al. Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/Akt pathway. Clin Exp Dermatol. 2020;45(2):194–201.

121. Sun Y, Tu Y, He L, Ji C, Cheng B. High mobility group box 1 regulates tumor metastasis in cutaneous squamous cell carcinoma via the PI3K/AKT and MAPK signaling pathways. Oncol Lett. 2016;11(1):59–62.

122. Marques AEM, Borges GA, Viesi CH, Vianna LMS, Ramos D, Castilho RM, et al. Expression profile of the PI3K-AKT-mTOR pathway in head and neck squamous cell carcinoma: data from Brazilian population. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;133(4):453–61.

123. Ghafoori-Fard S, Abak A, Tondro Anamag F, Shoorei H, Majdpoor J, Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137:111279.